NCT07447141

DBM-1152A Inhalation Solution in Chinese Healthy Subjects

A Randomized, Double-blind, Single-center, Placebo-controlled, Dose-escalation Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of DBM-1152A Inhalation Solution in Chinese Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A Inhalation Solution in healthy Chinese adult subjects.

Conditions

• Health
• Health Adult Subjects

Interventions

Type	Name	Description
DRUG	DBM-1152A Inhalation Solution	Single dose via oral inhalation nebulization.
DRUG	Placebo	Single dose of blank vehicle via oral inhalation nebulization.

Timeline

• Start date: 2023-12-24
• Primary completion: 2024-04-08
• Completion: 2024-04-08
• First posted: 2026-03-03
• Last updated: 2026-03-03

Locations

1 site across 1 country: China